GlassScriptPhysician profile
David Janicki
NPI 1336113638
$1,794.90
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $152 · 2021: $294 · 2022: $224 · 2023: $66.46 · 2024: $191 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $523.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $517.17 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $170.67 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $168.12 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $114.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.98 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $49.63 | 2024-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $39.52 | 2020-2021 | |
| Pfizer INC. | $22.89 | 2019 | |
| Neurelis, INC. | $22.01 | 2023 | Valtoco |
| Lundbeck LLC | $21.00 | 2024 | Rexulti |
| Eisai INC. | $17.42 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.54 | 2024 | Caplyta |
| Lifescan, INC. | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Janicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.